Daniel Heng
@DrDanielHeng
Followers
4K
Following
9K
Media
169
Statuses
2K
A medical oncologist that specializes in and focuses his research on urologic cancers.
Calgary, Alberta
Joined June 2016
We have moved to the Arthur Child Comprehensive Cancer Centre in Calgary! The largest free-standing cancer centre in Canada! $1.4 billion investment in patient care, research and hope. I love our team!@AHS_CancerCare @AHS_media @UCalgaryMed #YYC #medonc
9
12
90
I have to say that Arthur Child Cancer Center in Calgary is the most modern and state-of-the-art cancer center I have visited in Canada. It was great meeting you @DrDanielHeng - and you have built such an excellent team of colleagues there! And great to reunite with our
We have moved to the Arthur Child Comprehensive Cancer Centre in Calgary! The largest free-standing cancer centre in Canada! $1.4 billion investment in patient care, research and hope. I love our team!@AHS_CancerCare @AHS_media @UCalgaryMed #YYC #medonc
2
2
16
Voting for the ASCO election is now open! I am honored to be running as one of the candidates for the @ASCO Nominating Committee seat. Visit https://t.co/4riSVk7AQy to learn more about the candidates and place your vote! Thank you!!
18
100
232
Starting THIS FRIDAY November 7, 2025 DIRECT from NASHVILLE🇺🇸 #UromigosLIVE WE ARE THERE 🚨Stay Tuned for Coverage!! Presenting Our Ambassadors @Uromigos
@tompowles1
@brian_rini
@lalaniMD
@AmandaNizamMD
@DrKarineTawagi
@nataliagandur
@ReneeSaliby
@NazliDizman
@uromigosjapan
0
13
23
UPDATE FOR LITESPARK-011 NEWS FROM INDUSTRY/ Source MERCK Merck and Eisai announced that the Phase 3 LITESPARK-011 trial met its primary endpoint, showing that belzutifan plus lenvatinib significantly improved progression-free survival (PFS) 📈 compared with cabozantinib in
0
12
23
So now there are 3 +ve trials in adjuvant IO based treatment in high risk #kidneycancer. Looking forward to the full results. Belzutifan+pembro has DFS benefit at this point and awaiting OS. @oncoalert @KidneyCancer @IKCCorg
LITESPARK-022 Update NEWS FROM INDUSTRY Source: MERCK Merck announced positive topline results from the Phase 3 LITESPARK-022 trial, showing that pembrolizumab combined with belzutifan significantly improved disease-free survival 📈 compared with pembrolizumab alone in patients
0
8
19
Top GU Cancer Oncologists from @myESMO 2025 Explore more insights and data from #ESMO25: https://t.co/6VyXEIDUr8
#LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #MedicalOncology #ESMO2025 #GUCancer | @DrChoueiri | @MikeSerzanMD | @nataliagandur |
2
12
28
1/4 IMVIGOR011 shows ctDNA is a useful predictive and prognostic tool post cystectomy in muscle invasive bladder cancer #ESMO25 . ctDNA positive patients had DFS and OS benifits with atezolizumab. ctDNA negative patients are at a low risk of relapse/cancer death. @OncoAlert
7
86
178
Influential, state-of-the-art, as always presentation by @tompowles1 : Biomarker constructive positive trial on ctDNA-guided adjuvant win in MIBC. Atezolizumab improved DFS (HR 0.64; 9.9 vs 4.8 mo) and OS (HR 0.59; 32.8 vs 21.1 mo) vs placebo in ctDNA+ pts. #ESMO25 #BladderCancer
0
29
78
Huge congrats to @tompowles1 on shifting the paradigm in #bladdercancer (& frankly #cancer at large) w #IMvigor011, paving the way ctDNA as a tool for potentially allocating #adjuvant therapy. Bravo also on the simultaneous @NEJM publication!
0
31
77
Dear Colleagues at #ESMO25 Honored to present our OncoAlert 🚨 @tompowles1 🇬🇧 who Just presented IMvigor011 showing ctDNA🧬 is a useful predictive and prognostic tool post cystectomy in muscle invasive #BladderCancer with a Concomitant publication on the @NEJM , Direct from the
0
25
40
Don’t miss this excellent session starting right now! This is not an educational: these are proferred papers with new data! Very high-brow. #translational #basicscience #ESMO25 @NKI_nl @LoiSher @DrChoueiri @myESMO #hanover hall 7.2c
From bench to bedside: what’s shaping oncology? At #ESMO25 📌 Breastfeeding & breast cancer immunity 📌 mRNA vaccines & ICB synergy 📌 CAR T resistance in lymphoma 📌 Neoadjuvant immunotherapy in colon cancer 19 Oct 14:45–16:15 🔗 https://t.co/Ihir9Igg5i
0
5
21
#ESMO25 1058P Transcriptomic analysis identified key molecular pathways linked to platinum resistance: Findings may guide the development of predictive biomarkers and future therapeutic strategies #BestPosterAward
#TesticularCancer #TranslationalOncology
0
3
9
This is so cool. Imagine a world of 65% pT0 CR rates for muscle invasive bladder cancer. This is for cis ineligible but will there be scope creep? Looking forward to EV304 cis eligible. #esmo25 @OncoAlert #amazing
The bar is raised! Periop 🥪 EVP for cis ineligible (90%) or refusing (10%) MIBC = new SOC *KN905/EV302* ✅pT0 rate highest ever in MIBC 57% ITT, 65% cystectomy sub-pop ✅2yr EFS & OS on par w DDMVAC in cis eligible -cis eligible EVP🥪 trial *KNB15/EV304* readout awaited #ESMO25
2
20
59
Proud of @OncHahn for presenting LENCABO. OS appears similar but there is a PFS difference. There are toxicity differences so patient selection is important as usual. #ESMO25 @oncoalert
Clean trial of lenvatinib-everolimus vs cabozantinib in refractory #kidneycancer from @OncHahn @MDAndersonNews
#ESMO25 #ESMOAmbassadors @OncoAlert
2
10
26
The RAMPART is thankfully positive making it the second adjuvant immunotherapy trial in #kidneycancer along with KN564 with Pembrolizumab. Driven by high risk group. Included non clear cell but should look at that subgroup more. Awaiting OS. #ESMO25 @OncoAlert
📣 #ESMO2025: n=565 🇬🇧🇪🇸🇦🇺🇫🇷 RAMPART RCT; Durvalumab + tremelimumab 📈boosts DFS in resected RCC #kidneycancer (HR 0.65, 2-yr 84% vs 78%), esp. in leibovich high-risk pts (HR 0.52, 81% vs 67%). G3+ AES 8% monitoring versus 40% with durva+treme. OS data eagerly awaited! #kcsm
0
15
32
Join @AlbigesL @montypal @grimm_mo and I as we discuss #kidneycancer treatment updates and pearls at the Ipsen Symposium Saturday at 630pm @myESMO #ESMO25. Looking forward to great discussion! @OncoAlert @IKCCorg @CanUrolAssoc @kidneycan @KidneyCancer
0
9
28
Amazing Abstracts to be presented at #ESMO25 for Renal and Bladder. Peri operative bladder EV Pembro in cis ineligible, OPTIC RCC biomarker and RAMPART adjuvant RCC are highlights for me. Also KEYMAKER and a Len Eve vs Cabo study! @OncoAlert @myESMO @CanUrolAssoc
1
5
20
0
11
27